> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oculis Stock Slides 4%, Wiping Out $18 Million, After Setting Up Share Sale Program
- URL: https://www.bullished.co/oculis-stock-slides-4-wiping-out-18-million-after-setting-up-share-sale-program-fd08ca66/
- Published: 2026-11-04T17:42:18.000Z
- Updated: 2026-11-04T17:42:18.000Z
- Description: The eye-drug developer can now sell up to $125 million of new shares over time, a day after it posted third-quarter results.
- Author: Matteo Parrino
- Tags: Markets, OCS, Industry: Healthcare

[Oculis](https://www.bullished.co/tag/ocs/), a Swiss developer of eye-disease drugs, saw its shares fall [3.80% to $7.34](https://nz.finance.yahoo.com/news/oculis-holding-ag-ocs-reports-235507591.html?ref=bullished.co) in Wednesday trading as of 12:41 p.m. ET, erasing about $18 million in market value. The slide came the session after the company said in an [SEC filing](https://www.sec.gov/Archives/edgar/data/0001953530/000119312526445455/ocs-20261103.htm?ref=bullished.co) on Tuesday that it had set up a program to sell shares over time, up to $125 million.

## A $125 million share-sale ceiling

The program is an at-the-market offering, which lets a company sell new shares gradually at prevailing prices. It arrived alongside the company's [third-quarter results](https://www.globenewswire.com/news-release/2026/11/03/3394761/0/en/oculis-reports-q3-2026-financial-results-and-builds-momentum-toward-multiple-upcoming-pipeline-catalysts.html?ref=bullished.co), in which Oculis said cash and short-term investments of $252.0 million would fund operations into the second half of 2029.

The stock was on pace for its second drop of 3% or more this month. Its biggest one-day decline since Nov. 2, when it fell 6.7%, was also in view. After Wednesday's drop, the company was worth about $452 million.

## A stock down 62% this year

Oculis shares were down about 62% year-to-date as of Tuesday's close, against a gain of about 11% for the S&P 500, and had slid 13% over the prior month. That close was 77% below the highest close of the past year, set on May 11.

Oculis is a late clinical-stage biopharmaceutical company that develops drugs for eye diseases and diseases of the nerves connected to the eye. Its pipeline has three clinical-stage candidates: OCS-01, an eye drop in two late-stage trials for diabetic macular edema; Licaminlimab, an eye drop in a registrational trial for dry eye disease; and Privosegtor, a small molecule in registrational trials for two optic-nerve conditions.

## Trial readouts carry the story

Management said topline results from the PREDICT-1 dry eye trial are expected around year-end. CEO Riad Sherif said a positive result would position Licaminlimab to potentially become "the first precision medicine in ophthalmology."

Oculis holds an R&D Day on December 8, and the PREDICT-1 readout is due around year-end.

### Sources

- [Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates](https://nz.finance.yahoo.com/news/oculis-holding-ag-ocs-reports-235507591.html?ref=bullished.co) — Yahoo Finance
- [Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts](https://view.news.eu.nasdaq.com/view?id=baf881babae938405203a610febafdfed&lang=en&src=listed&ref=bullished.co) — view.news.eu.nasdaq.com
- [Oculis Reports Q3 2026 Financial Results and Builds](https://www.globenewswire.com/news-release/2026/11/03/3394761/0/en/oculis-reports-q3-2026-financial-results-and-builds-momentum-toward-multiple-upcoming-pipeline-catalysts.html?ref=bullished.co) — globenewswire.com
- [Oculis birtir uppgjör fyrir þriðja ársfjórðung 2026 og](https://www.globenewswire.com/news-release/2026/11/03/3394761/0/is/oculis-birtir-uppgj%C3%B6r-fyrir-%C3%BEri%C3%B0ja-%C3%A1rsfj%C3%B3r%C3%B0ung-2026-og-stefnir-a%C3%B0-mikilv%C3%A6gum-%C3%A1f%C3%B6ngum-%C3%AD-lyfja%C3%BEr%C3%B3un-%C3%A1-n%C3%A6stu-misserum.html?ref=bullished.co) — globenewswire.com
- [The company's filing (Oculis Holding)](https://www.sec.gov/Archives/edgar/data/0001953530/000119312526445455/ocs-20261103.htm?ref=bullished.co) — SEC filing
- [The company's filing (Oculis Holding)](https://www.sec.gov/Archives/edgar/data/1953530/000119312526445380/ocs-ex99%5F3.htm?ref=bullished.co) — SEC filing
- [Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates](https://www.zacks.com/stock/news/3022362/oculis-holding-ag-ocs-reports-q3-loss-lags-revenue-estimates?cid=CS-ZC-FT-fundamental%5Fanalysis|yseop%5Ftemplate%5F4-3022362&ref=bullished.co) — Zacks Investment Research

### More on Oculis Holding

- [Oculis Nine-Month Loss Narrows To CHF 57.1 Million, Helped By A Warrant Gain, As Dry Eye Readout Nears](https://www.bullished.co/oculis-nine-month-loss-narrows-to-chf-57-1-million-helped-by-a-warrant-gain-as-dry-eye-570461ff/)

[All Oculis Holding (OCS) coverage →](https://www.bullished.co/tag/ocs/)